Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (721-730 of 755) with videos related to

Pageof 76
Sort By:
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the American Thoracic Society|April 15, 2016
Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center ExperienceCatherine H Miele, Kristin Schwab, Rajeev Saggar, et al.
The New England Journal of Medicine|February 24, 2006
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg, Domenic J Reda, Crystal L Harris, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Pageof 76

Showing results (721-730 of 755) with videos related to

Sort By:
Pageof 76
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the American Thoracic Society|April 15, 2016
Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center ExperienceCatherine H Miele, Kristin Schwab, Rajeev Saggar, et al.
The New England Journal of Medicine|February 24, 2006
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg, Domenic J Reda, Crystal L Harris, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Pageof 76